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Abstracts
The number of innovative drugs reaching the market has decreased
steadily during the last several years to a handful per year. 
At the same time, the amount of resources allocated by the
pharmaceutical industries to promotion and marketing has
increased at a faster pace than those allocated to research and
development of new products. The paper presents the hypothesis
that for the large corporations, the production of me-too drugs
is more proﬁtable than to invest in research and development of
innovative products. Gaining a market share of me-too drugs
requires large investments in promotion and marketing, one
result of which is a division of labor among pharmaceutical ﬁrms.
Because small ﬁrms lack the large resources needed for promotion
and marketing, they carry out an increasing share of the research
and development and sell the patents to the large corporations.
De Cientíﬁcos a Comerciantes: La Transformación de
la Industria Farmacéutica y su Impacto en la Salud
El número de medicamentos que representan verdaderos avances
terapéuticos y que se comercializan anualmente ha ido decreciendo
durante los últimos años y ahora no son más que un puñado.
A la vez, la cantidad de recursos que la industria invierte en
promoción y marketing ha aumentado a una velocidad más rápida 
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que las inversiones en investigación y desarrollo de productos nuevos. Este trabajo discute la
hipótesis de que la producción de medicamentos “yo también (me too en inglés)” es más
lucrativa que la inversión en la investigación y desarrollo de productos innovadores. Para
poder controlar una parte signiﬁcativa del mercado con los medicamentos “yo también” la
industria necesita invertir considerablemente en promoción y marketing, y como consecuencia
ha habido una división de tareas entre los diferentes tipos de industria farmacéutica. Las
compañías pequeñas no tienen recursos suﬁcientes para la promoción y marketing, y cada vez
tienen un papel más importante en la investigación y desarrollo de productos innovadores,
luego estas compañías venden las patentes a las grandes corporaciones.
Des scientiﬁques aux marchandeurs: la transformation de l’industrie
pharmaceutique et l’effet sur la santé
Le nombre des médicaments innovateurs sur le marché diminue depuis plusieurs années
jusqu’au point où ils n’y sont qu’une poignée par an. En même temps, les ressources reparties
par les industries pharmaceutiques pour la promotion et la commercialisation augmentent
plus vite que celles qui sont reparties pour la recherche-développement des médicaments
nouveaux. Dans cet article, on formule l’hypothèse que quant aux entreprises les plus larges
il est plus proﬁtable de produire les “moi aussi” médicaments (qui sont à la mode) qu’il est
proﬁtable d’investir dans la recherche-développement des nouveaux produits efﬁcaces. Pour
gagner un marché des “moi aussi” médicaments il faut des investissements dans la promotion
et la commercialisation, dont un résultat est la division de travail parmi les entreprises
pharmaceutiques. Puisque aux petites entreprises, il manque les ressources assez larges pour
la promotion et la commercialisation, au lieu de les faire elles-mêmes, elles font la plupart de
la recherche-développement et vendent les brevets d’invention aux entreprises plus larges.
From Scientist to Merchants: The Transformation of the
Pharmaceutical Industry and its Impact on Health
For a number of years, the prices of medicines have increased at a higher
rate than inﬂation. The transnational innovative pharmaceutical industries,
known as big PhRMA, are large corporations which, regardless of the country
where they originated, are members of Pharmaceutical Research and
Manufacturers of America. Big PhRMA claims that to maintain the rhythm
of discoveries that have produced the miracle pills requires ever-growing
investments in research and development (R&D). Many organizations and
scholars have a different explanation for the high costs of medicines. According
to them, the high costs are explained by PhRMA’s interest in maintaining
22 • Antonio Ugalde and Núria Homedes
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huge proﬁts, high salaries and stock options for their executives, and more
fundamentally by the high expenditures in marketing and administration;
and are not a consequence, as the industry asserts, of the high costs of R&D.
Families USA uncovered that in 2001 the executives of 10 big ﬁrms received
an average compensation of US$23 million exclusive of unexercised stock
options, the average of which was US$48 million.1 Between 1991 and 2001,
the pharmaceutical industry was the most proﬁtable industry in the US or
about ﬁve-and-one-half times more proﬁtable than the average of the Fortune
500 companies,2 with an annual rate of return to shareholders, between 1996
and 2001, of 18.4 percent compared with a median return of 9.2 for the Fortune
500 shareholders.3
The high costs of promotion and marketing
It is difﬁcult to provide accurate ﬁgures of the amounts that big PhRMA
spends on promotion and marketing (P&M) because ofﬁcial industry ﬁgures
combine the expenditures on promotion, marketing and administration in a
single category, and in addition, as we will see, some ﬁrms report under R&D
expenditures that many consider should be included under P&M. Although
the industry presents a very different picture,4 there is an agreement among
independent researchers that the amount of funds spent on R&D of innovative
drugs are less than the amounts spent on administration, marketing, and
promotion by a factor of two or more.5
The following summary presents P&M activities carried out by big PhRMA:
1. Recruitment and training of drug representatives. In the US there are
100,000 representatives to inform physicians6 with an average salary of
US$62,400 and additional US$19,300 for cash bonuses.7
From Scientist to Merchants • 23
1 Families USA 2002, pp. 6–7.
2 Families USA 2002, p. 1; p. 3; p. 13.
3 Public Citizen 2001a, 12.
4 Pharmaceutical Research and Manufacturers of America 2004.
5 Families USA 2002, p. 3.
6 Golberg et al. 2004, http://www.pharmexec.com/pharmexec/article/article
Detail.jsp?id=80921
7 Golberg and Davenport 2005, http://www.pharmexec.com/pharmexec/article/
articleDetail.j sp?id=146596
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2. Advertisements in the professional literature and directed to the consumer
(DTC) (only the US and New Zeeland allow DTC advertising of prescription
drugs). It is estimated that in 2002, only in the US, the pharmaceutical
ﬁrms spent in promotion US$21 billion.8
3. The continuing education courses that all physicians are required to take
are almost entirely ﬁnanced by pharmaceutical industries. About US$1.9
billion are yearly spent by the industry in organizing conferences and
courses.9 There is a growing number of physicians that consider that such
funding creates a conﬂict of interest because each company uses these
courses to promote its drugs.10 In 2000 the industry sponsored 314,000
events for physicians.11 In addition to the courses, the industry sponsors
the participation of physicians at professional meetings, (in some instances
with a companion). In developing countries most physicians attend
international overseas meetings courtesy of the industry. It is understood,
that there is a quid pro quo and physicians who do not prescribe the ﬁrms’
products risk not being invited again. Wazana carried out a survey to
assess the impact of travel support, scholarships and gifts by the industry
on prescribing practices and found that they did inﬂuence them.12 There
is no information about the costs of these activities but given the large
number of events and scholarships granted it can be presumed to be
sizeable.
4. Paying well-recognized physicians to head Phase IV clinical trials. These
studies take place once a drug has been approved and is already com-
mercialized. Their purpose is to discover if the drug has any unknown
side effects, or if it can be used for other indications or for a special
population group. In some cases, these studies are required by the Food
and Drug Administration. These studies have also the non-written objective
of promoting the use of the drug.13 The pharmaceutical industry selects a
well-recognized specialist or renowned professor who will receive a
24 • Antonio Ugalde and Núria Homedes
8 Norris et al. p. 1.
9 Outterson 2004.
10 Brennan et al. 2006, pp. 431–432.
11 National Institute for Health Care Manangement 2001, http://www.nihcm.org/
ﬁnalweb/DTCbrief2001.pdf
12 Wazana 2000.
13 Angell 2004, pp. 161–166; Health Action International-Europe 2004, p. 4.
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substantial payment for carrying-out the study; the expectation is that
he/she would be able to ﬁnd that the drug has more beneﬁts or fewer
risks than other existing products. The sponsor expects that the professional
status of the director of the study will inﬂuence his/her colleagues to
prescribe the drug. There is no information on the number and costs of
Phase IV studies because most are not registered and the results are not
always disclosed. It has been estimated that the cost per patient enrolled
in a cardiovascular clinical trial in industrial societies ranges from US$5,000
to 10,000 depending on the complexity of the study, and the investigator
receives a fee between US$2000 and 3000 for each patient recruited for the
study.14 Phase IV studies are also carried out in developing countries, but
there is secrecy about payments to the carefully selected directors of the
studies, and information surfaces only when irregularities are brought to
the attention of the media or in audits.15 There is no information about
the costs of Phase IV studies, but they are bound to be high. We can assume
that the industry considers these expenditures to be part of its R&D costs,
all of which are tax deductible.
5. The industry sponsors research and pays scholars to write in leading
academic journals. It has been discovered that, compared to independent
research, sponsored research frequently ﬁnds more therapeutic advantages
and fewer side effects of drugs manufactured by the sponsoring
manufacturer; it is also known that the industry pays scholars to sign
articles written by ghost writers – also paid by the industry – that present
ﬁndings about the beneﬁts of the drugs, regardless if this is the case or
not.16 Subsequently, they buy thousands of reprints of these articles to be
distributed to physicians at meetings (without these purchases and drug
advertisements many medical journals would cease to exist). A survey
conducted by Martinson et al. found that 15.5 percent of US scientists
funded by the National Institute of Health had changed the design,
methodology or results of a study in response to pressure from a funding
agency.17 It is probable that research grants and costs related to publications
are categorized as R&D, even if its primary objective is promotion.
From Scientist to Merchants • 25
14 Bassand et al. 2003, p. 1172.
15 Acción Internacional para la Salud-Latin América 2003, p. 3; Orchuela 2006.
16 Collier and Iheanacho 2002, p. 1406; Koch 2003, p. 1161.
17 Martinson et al. 2005, p. 737.
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7. Grants to patients’ associations are used to make dubious claims about
the need to use certain drugs while minimizing their side effects. For
example, the National Sleep Foundation receives funding from ﬁrms that
market sleeping pills; for the years 1999 and 2000 Citizens for Better
Medicare, a group that without public knowledge had been created by
the pharmaceutical industry, spent US$65 million on “issue ads”.18 In the
European Union the funding by and links between the industry and 
the European Patients’ Forum, an advocacy group for the defense of
patients, have been uncovered.19 This group is a coalition that represents
several organizations of patients and has become the ofﬁcial mediator of
patients before the European Union. The scandals resulting from the
relations of organizations that purport to represent patients and the industry
has reached such levels that the new code of practice of the Association
of the British Pharmaceutical Industry requires from all industries working
in the United Kingdom full disclosure of the relations with and funding
of all advocacy groups.20 Figures of grants are not available but, compared
with other promotional and marketing costs are probably not high.
8. Distribution of millions of free samples to physicians, which in 2001 were
valued at US$11 billion, but it is not clear if this ﬁgure is based on their
retail or factory price; if the ﬁgure is based on retail prices, the ﬁrms may
obtain some additional tax beneﬁts because they are deducting more than
the real costs.
Other expenditures: Protecting and defending big PhRMA’s
interests
Like other corporations, big PhRMA ﬁrms spend large amounts of funds in
protecting and defending their interests. The following is a listing of these
activities:
1. Maintaining a large number of lobbyists to inﬂuence legislation and
persuade staff of the regulatory agencies in decisions that favor the industry
over the protection of citizens. In the US, in 2004 the drug industry had
26 • Antonio Ugalde and Núria Homedes
18 Public Citizen 2001b, p. 11.
19 Health Action International-Europe 2005.
20 Association of the British Pharmaceutical Industries 2005, pp. 32–33.
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1,291 lobbyists (52 percent were former federal ofﬁcials) at a cost of US$123
million, higher than any other industry, and in the seven years from 1998
to 2004 they lobbied more than 1,600 bills.21
2. Contributing donations to political parties and political candidates. In the
US in seven years, from 1998 to 2004, the industry contributed to federal
campaigns in the amount of US$87 million and the political contributions
to state governments amounted to US$46 million.22
3. Maintaining a top class team of lawyers to ﬁnd loopholes to extend the
market exclusivity, and to ﬁght legal and class action suits. When needed
the industry hires the best law ﬁrms. The total costs paid to the lawyers
and legal ﬁrms are not known, but it can be assumed that they are
substantial.
4. Payment of multimillion-dollar settlements and ﬁnes. For example, in
January of 2006, Bristol-Myers Squibb reserved US$185 million in
anticipation of a possible settlement of a class-action lawsuit ﬁled by users
of the once-promising heath drug Vanlev;23 in 2005 GlaxoSmithKline was
ﬁned US$150 million for the fraudulent price increase of two drugs; the
same year Serono, a Swiss biotech ﬁrm was ﬁned US$704 million for the
illegal promotion of a drug in the US; also in 2005 the government of
Brazil ﬁned twenty ﬁrms among them Abbott, Ely Lilly, Schering Plough,
Roche, Bristol-Myers Squibb, Aventis Pharma, Bayer, Glaxo Wellcome,
AstraZeneca, Boehringher Ingelheim, Aventis, Behring, Sanoﬁ-Synthelabo,
Wyeth-Whitehall for colluding to impede the commercialization of generics
in the country.24 Tap Pharmaceuticals paid US$875 million for a fraud
against the US government.25 In its ﬁrst case against Vioxx, the court
condemned Merck to pay US$253 million and some analysts have speculated
that the thousands of cases pending could cost Merck billions. Rarely, a
month goes by without at least one multimillion court case or a ﬁne against
a pharmaceutical ﬁrm.
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21 Asif Ismail 2005, http://www.publicintegrity.org/rx/printer-friendly.aspx?aid=723
22 Asif Ismail 2005, http://www.publicintegrity.org/rx/printer-friendly.aspx?aid=723
23 Anonymous 2006, 19.
24 Anonymous 2005a, p. 87.
25 Dembner 2001, p. A1.
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Costs of innovation vs. R&D
There is consensus that the cost of bringing highly innovative drugs to the
market is increasing, but there is disagreement among experts about the cost
of developing them. DiMasi et al. using conﬁdential data of 68 selected drugs
provided by ten ﬁrms arrived at the average ﬁgure of US$802 million (in US$
of 2000).26 These ﬁndings have been contested by several other researchers
that raised questions about the methodology and offered evidence that 
the price of a new innovative drug could be as low as one-fourth to half of
the DiMasi’s estimate.27 Critics of DiMasi indicate that the Tuft Center for the
Study of Drug Development, where he is based, receives large unrestricted
grants from the pharmaceutical industry, which has a vested interest in
demonstrating that the development of new drugs is very expensive in order
to justify high sale prices.
Indian pharmaceutical industries claim that in India innovative molecular
entities (NMEs) can be brought to the market for a fraction of the US$802
million, or about US$50 million.28 Although not always reﬂected in their
reports, some PhRMA industries are outsourcing parts of the development
process to China and India.
The industry’s lack of transparency makes it difﬁcult to know with certainty
the real allocations to innovative R&D and to other activities designed to
increase sales and proﬁts. If today’s industry’s estimate of producing a new
drug is US$1 billion and we multiply this amount by the average number of
innovative drugs per year (eight or nine), the total amount is considerably
less that the ﬁgure estimated by Family USA for P&M and administration
expenditures. According to this Foundation in 2001 the Merck, Pﬁzer, Bristol-
Myers Squibb, Abbot, Wyeth, Pharmacia (purchased by Pﬁzer in 2003), Eli
Lilly, Schering-Plough and Allergan spent US$45 billion for marketing,
advertisement and administration.
The shift from science to trade
By the time that a Lancet’s editorial noted in 2002 that big PhRMA was falling
behind in bringing to the market “truly new drug discoveries,”29 it was well
28 • Antonio Ugalde and Núria Homedes
26 DiMasi, Hansen and Grabowski 2003.
27 Light and Warburton 2005; Love 2003. 
28 Dyer 2004, p. 9.
29 Editorial 2002, p. 1341.
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known that the interest in research by big PhRMA was declining.30 Several
months earlier the National Institute for Health Care Management had
published a report documenting that of the 1035 drugs approved by the FDA
between 1989 and 2000, only 153 were highly innovative drugs (priority–rated
new molecular entities, see note 1 for the deﬁnition) or about 13 per year for
the 12-year period.31 The decline in innovation continued. During 1999–2002
the average yearly number of highly innovative drugs was reduced to eight.
Perhaps it was this deterioration that led Lancet to recommend that the
industry invest “preferentially in the creative minds in their laboratories”.32
The Lancet editor had failed to understand that big PhRMA’s interests have
shifted from innovative research to gaining a market share.
PhRMA expenditures in R&D more than doubled from 1993 to 2003.
According to the industry, in 2000 the private for-proﬁt sector invested US$35.4
billion in R&D,33 the number of approvals of new molecular entities declined
(See Figure 1).34
If PhRMA’s increasing expenditures in R&D cannot be attributed to the
high costs of producing a few new highly innovative drugs, the question that
needs to be answered is where do the rest of the R&D expenditures go. Our
hypothesis is that capitalism has forced the pharmaceutical industry to spend
a sizeable amount of R&D funds to produce drugs that do not add new
therapeutic value to the market. The purpose of these drugs is to compete
with innovative blockbuster drugs, those that generate more than US$1 billion
of yearly sales. It is this competition to gain a market share that forces industry
to make very large investments in P&M. Industries that fail in the competition
are bought out by the others. Those that support capitalism afﬁrm that
competition fosters innovation, but this does not seem to be the case in the
pharmaceutical sector, the contrary might be true.
The returns from developing true innovative molecular entities for an illness
or condition for which there is a high demand in Western nations are very
high, and the ﬁnancial success of the PhRMA industries depends on bringing
From Scientist to Merchants • 29
30 Kaplan and Laing 2004, p. 15.
31 National Institute for Health Care Management 2002, p. 3; Drake and Uhlman
1993, p. 72.
32 Editorial 2002, p. 1341.
33 World Health Organization 2004, p. 13.
34 Food and Drug Administration 2004, p. 2.
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into the market a few blockbusters. For example, the combined sales of Norvasc
(Pﬁzer), Zoloft (Merck), and Neurontin (Bristol-Myers Squibb) amounted in
2004 to over US$10 billion,35 and in 2002 Lipitor by itself represented US$7.4
billion or 21 percent of all Pﬁzer’s sales.36
30 • Antonio Ugalde and Núria Homedes
35 Anonymous 2005b, p. 21.
36 Simons 2003, http://money.cnn.com/magazines/fortune/fortune_archive/
2003/01/20/ 335643/index.htm
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Source: Ian M. Cockburn. The Changing Structure of the Pharmaceutical Industry.
Health Affairs, 2004; 3(1): 10-22.
Note: Line relates to the right y axis and denotes worldwide R&D spending by PhRMA
member companies according to their official figures. Inflation-adjusted to constant
2002 US$. The source for new molecular entities approved is the US Food and Drug
Administration Center for Drug Evaluation and Research. New molecular entities
may not be innovative, i.e. they may not add any therapeutic value to the drugs
already in the market. Some of the new molecular entities are withdrawn from the
market when post-commercialization surveillance uncovers serious side effects; the
number of withdrawals has increased in recent years. Some new molecular entities
are for ‘created diseases’ and therefore of little therapeutic value.
Figure 1 Research and Development expenses and new molecular entities
approved 1970–2002 
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If the ﬁrm that launches a blockbuster drug can, through patents and other
means, hold market exclusivity and control the price for a number of years,
one would think that the company would not need too many breakthroughs
and that most efforts would be focused on extending the market exclusivity
period. But when there is a breakthrough, a new blockbuster, other big PhRMA
ﬁrms try to beneﬁt from the discovery by developing similar drugs that will
use the same action mechanism and produce very similar effects, these
medicines are called “me-too drugs.” In some cases, the me-too drug may
offer some advantages over the original product (i.e. could be easier to use,
safer or more convenient to administer) but this is not always the case. There
is little difference among the statins that are available in the market: Mevacor,
Lipitor, Zocor, Pravachol, Lescol and the more recent one Crestor; but the
manufactures of these drugs have to ﬁght to increase their market share.
To capture the market the companies incur in large P&M expenditures to
convince prescribers, patients and the community at large that their product
is better than that of the competitor. There are cases where pharmaceutical
companies reach the market with a similar product almost simultaneously,
and during the ﬁnal development stages the companies race to reach the
market ﬁrst and capture the clientele (i.e. Vioxx and Celebrex). Regardless of
the process, once me-too drugs are in the market, all owners have the same
common interest in extending the life of the patents.
The competition to gain a market share of blockbusters has changed the
behavior of big PhRMA and explains the need for the activities described
earlier that require large outlets in P&M. In 1999, Merck placed Vioxx in the
market and the following year spent US$161 million advertising the drug to
gain a market share from Pﬁzer’s Celebrex that had been launched earlier.37
By Februrary of 2004, before Vioxx was withdrawn from the market, it
controlled 37 percent of the market of the Cox-2 inhibitors (Vioxx, Arcoxia,
Celebrex and Bextra), and Celebrex 41 percent. The industry had estimated –
before the side effects of Cox-2 inhibitors were made public – that in 2009
the total sales of these medicines would be US$8.5 billion.38
The priority given to M&R over biological sciences has an important effect
in the organizational culture and behavior of big PhRMA ﬁrms. If what is
From Scientist to Merchants • 31
37 Bowe 2004a, p. 14.
38 Bowe 2004b, p. 16.
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considered relevant is P&M, then selecting the leadership, the status and
rewards within the organization are bound to be granted to those employees
that excel in the marketing and promotional side of the corporation rather
than to the scientists.
The promotion and marketing of new-disease and life-style drugs
Drug sales are not exclusively based on the needs of patients to get healthy.
The parameters used to diagnose risk factors for diseases have been recently
modiﬁed with the help of the industry. We have seen modiﬁcations in blood
pressure thresholds that have resulted in a signiﬁcant number of patients
being classiﬁed as borderline or hypertensive, in the glucose levels to diagnose
pre-diabetic conditions, and in the optimal levels of LDL cholesterol. According
to Moynihan and Cassels eight of the nine members of the panel that in 2004
revised the cholesterol parameters and lowered them were on drug company
payrolls, a lowering that trebled the anti-cholesterol drugs adults in need of
statins to 40 million, and nine of the 11 experts on the panel that lowered the
parameter for hypertension had ﬁnancial links to the industry.39 In addition,
behavioral problems have been transformed into new diseases. Such are the
cases of attention deﬁcit, social anxiety disorder, premenstrual dysforic disorder,
and gastroesophageal reﬂux disease.40 Psychiatrists also on the pay-rolls of
the pharmaceutical industry have offered a medical explanation for the new
disease known as attention deﬁcit.
Blockbusters are also developed to achieve certain desirable conditions or
to provide a chemical solution to a health problem that some patients could
resolve with less risks through behavior modiﬁcation, these are called life-
style drugs. The deﬁnition of what constitutes a life-style drug is controversial41
but there is agreement that certain drugs to control obesity, to treat male
baldness, to enhance the erectile function in healthy young men, or to control
smoking can be classiﬁed as life-style drugs. The number of new-disease and
life-style drugs is growing. After parameters or thresholds are ofﬁcially
32 • Antonio Ugalde and Núria Homedes
39 Moynihan and Cassels 2005.
40 Moynihan et al., 2002; Angell 2004, pp. 86–87.
41 Lexchin, 2001, p. 1449.
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modiﬁed or new diseases are created, the P&M machine of big PhRMA starts
working to promote sales of medicines for these conditions.42
The consolidation of the industry and division of labor
In the past years the pharmaceutical industry has seen a strong consolidation.
In 1987 the top ten drug manufacturers had 27.5 percent of the world’s
pharmaceutical market and by 2000 the percentage increased to 45.7.43 It could
not be otherwise, because the need to spend ever-increasing amounts in M&P
requires very large amounts of capital that only very large corporations can
accumulate. But consolidations have moved big PhRMA further away from
basic research. Analyzing several mergers, Pignarre concludes that the
consolidation of the pharmaceutical industry has had a negative impact on
innovation.44
The expenditures on P&M by big PhRMA are of such a magnitude that
small ﬁrms cannot compete, and, therefore, few small ﬁrms venture into
marketing; this has become the feud of the ever-bigger corporations. The
small industries and big PhRMA have understood that a division of labor is
ﬁnancially more attractive for both of them. Small corporations engage in
R&D of new molecular entities and big PhRMA buys the patents and takes
responsibility for marketing those drugs that are expected to generate sales
of over US$250 million per year for at least 14 years;45 if a small ﬁrm has
several promising drugs in the pipeline, big PhRMA may decide to buy it
out. In 2004, Pﬁzer purchased small Medarex Inc.46 and Roche signed 40
contracts to own the research ﬁndings and the commercialization permits of
drugs in the process of being developed.47 In 2005 Roche purchased tiny
BlycArt Biothcnology.48
The relations between big PhRMA and the small industries are not always
easy. Tamiﬂu (oseltamivir), the drug for the treatment of the common ﬂu,
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illustrates the division of labor between large and small pharmaceutical
industries and some of the tensions that these arrangements generate. Tamiﬂu
was discovered and developed by Gilead, a small ﬁrm, and in 1999 Roche,
the giant Swiss pharmaceutical, obtained the exclusivity for its production
and marketing. The contract between the two corporations stipulated that
Gilead would receive, on top of other pecuniary compensations, a percentage
of the revenues generated by Tamiﬂu sales. Before the aviar pandemic, the
sales of Tamiﬂu were modest and limited to the ﬂu season. Gilead started
litigation claiming that Roche was not promoting adequately the drug, that
is, Roche was not doing its part in the division of labor. The conﬂict was
agreeably settled when purchase requests for Tamiﬂu suddenly skyrocked
with the threat of the aviar ﬂu. Instead of litigation the two companies agreed
to cooperate to ﬁll the orders from more that 50 countries that decided to
stockpile. It was estimated that sales of Tamiﬂu could reach US1bn in 2005
and 2006.49 Tamiﬂu, by an unpredictable event, became a blockbuster.
The case of the small Tanox is also illustrative. In 2000 Tanox began clinical
trials of a NME known as TNX-901, a product to control allergic reactions to
peanuts.50 Two big PhRMA ﬁrms, Genetech and Novartis, were cooperating
with Tanox in the production of TNX-901 and the same year forced Tanox to
discontinue the trials and develop Xolair, a product that Genetech had in the
pipeline to treat the same allergy. Tanox refused and brought Genetech and
Novartis to court. As of 2005 Xolair has not proven to be effective to treat the
allergy. It is very possible that if the clinical trials had continued, TNX-201
would be today the only available treatment for the allergies caused by
peanuts.51
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50 New molecular entity (NME) is a drug whose active ingredient has never before
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The health impact
As discussed, big PhRMA needs to have market exclusivity to delay the entry
of generics into the market and keep the monopoly prices. Once a drug looses
market exclusivity, the prices fall rapidly to as little as 20 percent of the
original drug.52 Through legislation, loopholes and illegal avenues, PhRMA
ﬁrms have been successful in extending the life of the patents.
All over the world, high drug prices are the main access barrier. It is
estimated that between 1.3 and 2.1 billion people do not have access to essential
medicines.53 Most of those without access are the poor. The poor that have
access to drugs spend the most of the health expenditures in the purchase of
drugs and have to pay for them out-of-pocket.54 High prices also impact
negatively in the adequate use of pharmaceuticals; for example, poor people
cannot afford the entire treatment. In the case of antibiotics, incomplete
treatments facilitate the development of microbial resistance to commonly
used antibiotics and generate the need to develop newer and more expensive
drugs.
A strategy to compete with generics is the promotion of brand loyalty to
keep consumers buying their products in the middle of aggressive inroads
from competitors. As a result, often in complicity with physicians and
pharmacists, patients, including the poor, pay unnecessarily higher prices or
purchase less medicine than the amount prescribed and cannot complete the
entire course of treatment.
Due to aggressive marketing, life-style drugs can be easily abused; one
well-known case is that of the drugs for erectile dysfunction such as Viagra
(sildenaﬁl) of Pﬁzer, Cialis (tadalaﬁl) of Lilly, or Levitra (vardenaﬁl) developed
jointly by Bayer and GlaxoSmithKline. These companies have sold millions
of pills without prescription in many countries. In some Latin American
countries ads, which at times violated the norms established by regulatory
agencies, were responsible for generating unnecessary demand for drugs in
this therapeutic group.55 In Argentina, it was estimated that the large majority
of users of these drugs were men between 30 and 45 years of age who did
not suffer erectile dysfunctions;56 and in Mexico in 2002 Viagra sales amounted
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to US$550 million. Authorities and the industry have alerted that there are
cases of coronary problems and blindness associated with their use.
Big PhRMA cannot afford to develop drugs that do not guarantee high
returns because it needs resources for the P&M expenditures. It is for this
reason that there are no drugs to cure diseases that affect millions of poor
people worldwide (forgotten diseases) or a few persons (rare diseases, of
which there are an estimated number of 500057).58 WHO estimates that only
10 percent of R&D funds are allocated to ﬁnding cure to diseases that affect
90 percent of the world’s population;59 and Sheila Shettle, Communications
Ofﬁcer of Médecins Sans Frontières afﬁrmed that of 1,556 new products
marketed globally between 1975 and 2004, only 20 or 1.3 percent were for
tropical diseases and tuberculosis.60
In a consumer’s society, success requires the creation of unnecessary
demands. This basic rule of capitalism applies to the pharmaceutical industry.
All drugs are powerful chemicals and their unnecessary use can cause serious
iatrogenetic effects. Over prescription and self-prescription caused by P&M
has costly health and economic costs. In 1993, Wolfe and collaborators published
a list containing the number and types of adverse drug reactions that occurred
in the US such as thousands of injuries from trafﬁc accidents, of hip fractures
from falls, of life-threatening heart toxicity, of mental impairment, of drug-
induced parkinsonism and tardive dyskenesia; they estimated that in 1990
only among those 65 years of age and above there were 650,000 hospitalizations
caused by adverse drug reactions.61 Obviously, many of them were produced
by errors. If this study would be replicated today, the result would be worse
because the average number of medicines consumed per person in the US
has increased, in part due to aggressive P&M. The situation is even worse in
developing nations where regulations of prescription and dispensation of
drugs are very poorly enforced and the educational levels of the majority 
are low.
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Conclusions
The model followed by big PhRMA is very questionable. In spite of the many
attempts to control the behavior of the industry, the efforts have not changed
the model. In fact, the model for the production of pharmaceuticals should
be exactly the opposite, a minimum of expenses in P&M and a full dedication
to ﬁnd solutions to the diseases that continue to afﬂict mankind. If the efforts
of the industry were dedicated exclusively to the discovery of new innovative
drugs, it is very possible that the industry would proﬁt from the sales of
drugs for rare and neglected diseases, and governments could afford to
subsidize all drugs needed by their citizens. Perhaps in a capitalist market is
not possible to change the current pharmaceutical model. If this is the case,
there will be little choice but to ﬁnd new solutions in which the public sector
will have to play a signiﬁcant role.
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